Medicines that target the programmed cell death 1 (PD-1)–programmed death-ligand 1 pathway, also known as immune checkpoint inhibitors, have dramatically changed the treatment of various types of cancers, including melanoma [47, 48]. Here, PDCD1 is linked to melanoma.